<div><p><strong><b>Background:</strong> </b>Alcoholic associated liver disease (AALD) is a poorly characterized pathology characterized by <span> </span>steatosis, inflammation and fibrosis. The lack of an animal model which recapitulates key features of AALD has been a major limitation in understanding its etiology and in the development of effective therapies.

<div><p><b>Background:</p> </b><p>Long term reduction and alcohol abstinence have been known to reduce both short and long term mortality in patients with Alcohol associated Liver diseases (AaLD). Naltrexone, despite being known efficacy in Alcohol dependence, has not been tested in liver disease patients. We aimed to evaluate six and twelve month abstinence rates (and new onset decompensation events over 12 months) after 12 weeks of Naltrexone (50 mg) compared with placebo in patients with underlying AaLD.</p>

<div><p><b>Background: </b>The non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. We aim to develop a novel non-invasive model for predicting CSPH in patients with compensated advanced chronic liver disease, and investigate whether carvedilol could prevent hepatic decompensation in high-risk CSPH patients stratified by the novel model.</p>

<div><p><strong><b>Background:<span> </b></span></strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with high morbidity and mortality among vulnerable populations. We hypothesized the social determinants of health (SDOH), downstream social risks, and health behaviors impact access to curative therapies.</p>

<div><p><b>Background: </b>Food insecurity can increase the risk for NAFLD. We assessed the association between food insecurity and NAFLD among adolescents in the United States.</p>

<div><p><b>Background: </b>The rising prevalence of alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) has led to increases in the need for liver transplantation (LT). The purpose of our study was to investigate disparities in access to LT, and whether those disparities were consistent across etiology of liver disease.</p>

<div><p><b>Background: </b>Cross-sectional studies have identified individuals from sub-Saharan Africa with (SSA) chronic hepatitis B (CHB) as a potential risk group for hepatocellular carcinoma (HCC) and advocate enrolment in an HCC surveillance program even in the absence of cirrhosis. However, the incidence of HCC and performance of HCC risk scores in this population are unknown.</p>

<div><p><b>Background:</p> </b><p style="font-weight: 400;">Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) has extremely high prevalence in the US and globally with increasing incidence of morbidity and mortality in the population.

<div><p><b>Background:</p> </b><div><p><span lang="EN-US">Despite recent developments, it is still very difficult to differentiate hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (iCCA). Clinically available methods such as CT, MRI, and contrast-enhanced ultrasound require the highest level of investigator experience to reliably differentiate between HCC and iCCA.

<div><p><b>Background: </b>Immune checkpoints (CTLA4 &amp; PD1) are inhibitory pathways that block aberrant immune activity and maintain self-tolerance. Tumors co-opt these checkpoints to avoid immune destruction. Immune Checkpoint Inhibitors (ICIs) activate immune cells and restore their tumoricidal potential, making them highly efficacious cancer therapies.